|
RNF8 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.90199999972052E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.58640000031052E-07 |
| Normal-vs-Stage2 |
6.314300E-02 |
| Normal-vs-Stage3 |
1.199730E-04 |
| Normal-vs-Stage4 |
1.0942999995045E-07 |
| Stage1-vs-Stage2 |
7.639800E-02 |
| Stage1-vs-Stage3 |
5.858400E-01 |
| Stage1-vs-Stage4 |
1.031350E-01 |
| Stage2-vs-Stage3 |
2.172000E-01 |
| Stage2-vs-Stage4 |
9.218500E-03 |
| Stage3-vs-Stage4 |
7.642300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.80430000004972E-07 |
| Normal-vs-AfricanAmerican |
1.976000E-01 |
| Normal-vs-Asian |
3.08650000002686E-06 |
| Caucasian-vs-AfricanAmerican |
6.275800E-02 |
| Caucasian-vs-Asian |
3.288200E-01 |
| AfricanAmerican-vs-Asian |
1.747790E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.41850000000099E-05 |
| Normal-vs-Female |
1.19070000004218E-06 |
| Male-vs-Female |
6.175000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.48279999945267E-07 |
| Normal-vs-Age(41-60Yrs) |
2.12619999999664E-05 |
| Normal-vs-Age(61-80Yrs) |
3.5608999999992E-05 |
| Normal-vs-Age(81-100Yrs) |
5.743700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.118400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.798400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.888200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.093000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.728800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.247200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.683800E-01 |
| Classical-VS-Follicular |
9.559000E-01 |
| Classical-VS-Other |
3.396400E-01 |
| Classical-VS-Normal |
1.55155999999046E-05 |
| Tall-VS-Follicular |
3.689600E-01 |
| Tall-VS-Other |
7.322800E-01 |
| Tall-VS-Normal |
6.46249999999293E-05 |
| Follicular-VS-Other |
4.263800E-01 |
| Follicular-VS-Normal |
2.976300E-04 |
| Other-VS-Normal |
4.716200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.14979999999532E-05 |
| Normal-vs-N1 |
5.2231999836394E-09 |
| N0-vs-N1 |
1.336850E-03 |
|
|
